Dr. Patrick M. Dennis, MD
Emergency Medicine (Emergency Medical Services (Emergency Medicine) Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medical Services (Emergency Medicine) Physician primary
LA license MD.200267 · LA license MD200267
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $79.03 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $79.03 |
|---|
| Food and Beverage | $79.03 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 11 companies. The companies reported $2,653,798 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
ModernaTX, Inc. · Completed · NCT07089706 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3 multicenter parallelgroup openlabel study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion f subunit vaccine when coadministered with herpes zoster subunit vacc…
Pfizer Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06625060 - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A phase iii, open-label, randomized, controlled, multi-country study t
GlaxoSmithKline, LLC. - Study name not reported
Lexicon Pharmaceuticals, Inc. - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine
Merz Pharmaceuticals, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.